US Patent Issued to Regeneron Pharmaceuticals, Inhibrx Biosciences on Sept. 23 for "CLL-1 targeted immunotherapies" (Massachusetts, California Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,315, issued on Sept. 23, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) and Inhibrx Biosciences Inc. (La Jolla, Calif.).

"CLL-1 targeted immunotherapies" was invented by Jordan Jarjour (Cambridge, Mass.), Mark Pogson (Cambridge, Mass.), Wai-Hang Leung (Cambridge, Mass.), Lucas Rascon (La Jolla, Calif.), Angelica Sanabria (La Jolla, Calif.), John C. Timmer (La Jolla, Calif.) and Brendan P. Eckelman (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one ...